Persistent risk of cardiovascular diseases despite using established medical therapies require additional therapeutic approach. Considerable attentions have focused on novel agents targeting high-density lipoprotein (HDL) because of its atheroprotecive functions. HDL has the abilities to promote reverse cholesterol transport and modify inflammatory, oxidative, apoptotic, and endothelial pathways. Numerous basic and preclinical studies have demonstrated the beneficial effects of HDL targeting therapy on atherosclerosis. While recent clinical trials failed to prove favourable effect of HDL targeting therapies on cardiovascular outcomes, further search still continues to identify effective therapeutic approach targeting HDL due to its attractive anti-atherosclerotic properties. Recently, different types of agents modulating HDL have been developed and investigated or currently under clinical trial. Plaque imaging has been increasingly employed to evaluate the efficacy of these therapies because of its association with cardiovascular outcomes. This modality will further play an important role in the assessment of novel drugs modulating HDL in the future. The current article will review characteristics of HDL, its atheroprotective effects, HDL targeting therapies and its efficacy on atherosclerosis evaluated by plaque imaging modalities.
I. Introduction
Over the course of the last 2 decades, large randomized controlled trials have consistently demonstrated anti-atherosclerotic effect of lowering low-density lipoprotein (LDL) cholesterol with statin. 1, 2) As a result, LDL cholesterol lowering has become an integral component of therapeutic strategies in the prevention of cardiovascular diseases. 3, 4) However, despite using a statin, substantial amount of cardiovascular events is still observed. 5, 6) These observations indicate the need to develop new therapeutic strategies modulating additional therapeutic target associated with residual cardiovascular risks. In the recent years, considerable attentions have focused on therapeutic approach targeting high-density lipoprotein (HDL) because of its biological properties which include promoting reverse cholesterol transport and modifying inflammatory, oxidative, apoptotic, and endothelial pathways. 7-9) An inverse relationship between HDL cholesterol (HDL-C) level and cardiovascular outcomes in population studies supports this therapeutic concept. [10] [11] [12] In addition, infusing HDL or transgenic expression of its major protein has been shown to favourably modify plaque size and composition in animal models. [13] [14] [15] [16] [17] While recent clinical trials fail to prove the benefit of HDL-C raising therapy to cardiovascular outcomes, [18] [19] [20] [21] further search still continues to identify effective therapeutic approach targeting HDL.
Technological advances in plaque imaging modalities enable to directly visualize atherosclerotic plaques within vascular beds.
Recently, plaque imaging has been increasingly employed to evaluate the efficacy of novel therapies on atherosclerotic lesions because several measures evaluated by imaging modalities have been reported to associate with cardiovascular outcomes. [22] [23] [24] As a result, it is likely that atherosclerosis imaging will become an integral component of early clinical development of novel therapies including HDL modifying agent. This review will summarize characteristics of HDL, therapeutic approaches modulating HDL and its efficacy on atherosclerosis evaluated by plaque imaging modalities.
II. Structure of HDL
The HDL particles consist of an outer amphipathic layer of free cholesterol, phospholipid, and several apolipoproteins on the surface, with a triglyceride and cholesterol ester-rich hydrophobic core. 25, 26) The main protein component of HDL is apolipo- [pre-β (very small pre-β1, large pre-β2 and pre-β3), α1, 2, 3 or 4]
( Fig. 1) . 27) It has become increasingly important to determine the clinical relevance of each individual HDL subfraction associated with atheroprotective property because recent study reported that atheroprotective ability of HDL varies according to its subclasses. [28] [29] [30] It is important to assess the effects of therapeutic intervention in HDL on its structural heterogeneity.
III. Protective Properties of HDL toward Atherosclerosis
HDL has been demonstrated to exhibit a variety of atheroproteicve properties (Table 1) .
1) Reverse cholesterol transport
Promoting reverse cholesterol transport is the main anti-ath- (27) . 70) or inflammatory diseases. 71 
V. HDL targeting therapy and plaque progression
There are already several available agents to raise HDL-C level (Table 2) . Also, novel therapies targeting HDL have been developed and tested or under investigation in clinical trials (Table 2) . 
Serial IVUS imaging
There was no significant difference between combined group of HDL infusion vs placebo (change in percent atheroma volume, -3.4 vs -1.6%, p=0.48, change in total atheroma volume, -5. 
This study did not find any significant differences with regard to plaque progression in placebo or 3, 6 or 12 mg/kg CER-001 group. and HDL-C levels (10.9 vs 7.7%), and there were no significant differences between the groups (p=0.18 and 0.32, respectively).
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